Join Diane Ramsden, PhD, and Lindsey Whaley, MS, for an inside look at TruVivo™, a novel all-human in vitro hepatocyte system developed by LifeNet Health LifeSciences.

Dr. Jack Vanden Heuvel discusses the use of cell-based reporter assays for nuclear receptor profiling to efficiently prioritize drug candidates and minimize off-target effects.

Dr. Jeffrey Silva explores the role of mass spectrometry-based proteomics on drug discovery, disease mechanisms, and biomarker identification.

Dr. Sam Sternberg discusses a novel CRISPR-Cas9 system using programmable, RNA-guided transposase, and highlights its implications for kilobase-scale genome engineering in cell and gene therapies.

Key opinion leaders in cardiovascular physiology and bioengineering discuss best practices and challenges when modeling cardiomyopathies and other cardiovascular diseases using stem cells, engineered tissues and other novel platforms.

Dr. Anna Borgström and Dr. Frauke Greve present the latest advancements in hepatic safety assessment using 3D liver spheroids.

Join Bruker experts online for 1 hour every month in this essential training program designed for NMR Scientists.

Dr. Audrey Dubourg and Dr. Gareth Guenigault explore the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.

In this webinar, Dr. Ejvind Mørtz discusses the benefits and applications of mass spectrometry (MS)-based host cell protein (HCP) analysis and why HCP ELISAs are insufficient for documenting product-related impurities. Watch to learn where to apply the assay in a typical process and what you gain from deploying it to your workflow.

Dr. Oscar Perez and Dr. Jon Weidanz discuss the basis of the FAST-HDR gene-editing system and present case studies highlighting several applications.

Andrew G. Taylor, PhD provides an overview of processes by which drugs are metabolized and discusses the importance of drug metabolism and drug-drug interaction studies.

Dr. Martin Stahl describes the use of patient-derived intestinal organoids to assess the toxicity of potential therapeutic compounds and study barrier function in a human-specific model system.